Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

AL. Cunningham, TC. Heineman, H. Lal, O. Godeaux, R. Chlibek, SJ. Hwang, JE. McElhaney, T. Vesikari, C. Andrews, WS. Choi, M. Esen, H. Ikematsu, MK. Choma, K. Pauksens, S. Ravault, B. Salaun, TF. Schwarz, J. Smetana, CV. Abeele, P. Van den Steen,...

. 2018 ; 217 (11) : 1750-1760. [pub] 20180505

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035361

Background: The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods: Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results: After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions: Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination. Clinical Trials Registration: NCT01165177; NCT01165229.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035361
003      
CZ-PrNML
005      
20191014121821.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/infdis/jiy095 $2 doi
035    __
$a (PubMed)29529222
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cunningham, Anthony L $u The Westmead Institute for Medical Research, University of Sydney, Australia.
245    10
$a Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older / $c AL. Cunningham, TC. Heineman, H. Lal, O. Godeaux, R. Chlibek, SJ. Hwang, JE. McElhaney, T. Vesikari, C. Andrews, WS. Choi, M. Esen, H. Ikematsu, MK. Choma, K. Pauksens, S. Ravault, B. Salaun, TF. Schwarz, J. Smetana, CV. Abeele, P. Van den Steen, I. Vastiau, LY. Weckx, MJ. Levin, ZOE-50/70 Study Group,
520    9_
$a Background: The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01B Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods: Participants (ZOE-50: ≥50; ZOE-70: ≥70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing ≥2 of 4 activation markers assessed (CD42+) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results: After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD42+ T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained ≥5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions: Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination. Clinical Trials Registration: NCT01165177; NCT01165229.
650    _2
$a adjuvancia imunologická $x farmakologie $7 D000276
650    _2
$a senioři $7 D000368
650    _2
$a protilátky virové $x imunologie $7 D000914
650    _2
$a CD4-pozitivní T-lymfocyty $7 D015496
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a herpes zoster $x imunologie $7 D006562
650    _2
$a vakcína proti pásovému oparu $x imunologie $7 D053061
650    _2
$a virus varicella zoster $x imunologie $7 D014645
650    _2
$a lidé $7 D006801
650    _2
$a buněčná imunita $x imunologie $7 D007111
650    _2
$a humorální imunita $x imunologie $7 D056724
650    _2
$a imunogenicita vakcíny $x imunologie $7 D000071497
650    _2
$a lipid A $x analogy a deriváty $x farmakologie $7 D008050
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a saponiny $x farmakologie $7 D012503
650    _2
$a vakcinace $x metody $7 D014611
650    _2
$a subjednotkové vakcíny $x imunologie $7 D022223
650    _2
$a proteiny virového obalu $x imunologie $7 D014759
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Heineman, Thomas C $u GSK, King of Prussia, Pennsylvania.
700    1_
$a Lal, Himal $u GSK, King of Prussia, Pennsylvania.
700    1_
$a Godeaux, Olivier $u GSK, Wavre, Belgium.
700    1_
$a Chlibek, Roman $u Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic.
700    1_
$a Hwang, Shinn-Jang $u Department of Family Medicine, Taipei Veterans General Hospital, and National Yang Ming University School of Medicine, Taiwan.
700    1_
$a McElhaney, Janet E $u Health Sciences North Research Institute, Sudbury, Ontario, Canada.
700    1_
$a Vesikari, Timo $u Vaccine Research Center, University of Tampere, Finland.
700    1_
$a Andrews, Charles $u Diagnostics Research Group, San Antonio, Texas.
700    1_
$a Choi, Won Suk $u Division of Infectious Disease, Department of Internal Medicine, Korea University College of Medicine, Seoul.
700    1_
$a Esen, Meral $u Institute of Tropical Medicine, University Clinic of Tuebingen, Germany.
700    1_
$a Ikematsu, Hideyuki $u Japan Physicians Association, Kanda, Chiyoda-ku, Tokyo.
700    1_
$a Choma, Martina Kovac $u GSK, Rockville, Maryland.
700    1_
$a Pauksens, Karlis $u Department of Infectious Diseases, Uppsala University Hospital, Sweden.
700    1_
$a Ravault, Stéphanie $u GSK, Rixensart, Belgium.
700    1_
$a Salaun, Bruno $u GSK, Rixensart, Belgium.
700    1_
$a Schwarz, Tino F $u Central Laboratory and Vaccination Centre, Klinikum Würzburg Mitte, Standort Juliusspital, Germany.
700    1_
$a Smetana, Jan $u Faculty of Military Health Sciences, University of Defense, Hradec Kralove, Czech Republic.
700    1_
$a Abeele, Carline Vanden $u GSK, Wavre, Belgium.
700    1_
$a Van den Steen, Peter $u GSK, Wavre, Belgium.
700    1_
$a Vastiau, Ilse $u GSK, Wavre, Belgium.
700    1_
$a Weckx, Lily Yin $u Federal University of Sao Paulo, Brazil.
700    1_
$a Levin, Myron J $u Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora.
710    2_
$a ZOE-50/70 Study Group
773    0_
$w MED00002745 $t The Journal of infectious diseases $x 1537-6613 $g Roč. 217, č. 11 (2018), s. 1750-1760
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29529222 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014122245 $b ABA008
999    __
$a ok $b bmc $g 1452021 $s 1073911
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 217 $c 11 $d 1750-1760 $e 20180505 $i 1537-6613 $m The Journal of infectious diseases $n J Infect Dis $x MED00002745
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace